

Media Release

Maryland Biotechnology Center as new partner of Venture Valuations Biotechgate and USA Life Sciences Database

ZURICH / MARYLAND, April 2009 - Finding partners and learning about Maryland's biotechnology industry is now easier than ever before. With the Maryland Biotechnology Center, Swiss based Venture Valuation found another local partner to expand its international biotech and life sciences database Biotechgate.

The database for Maryland is part of the Global Biotech Company Database, Biotechgate (www.biotechgate.com), with more than 13'000 company profiles. Biotechgate comprises databases from many countries such as Canada, France, Germany, India, Italy, Scandinavia, Switzerland, UK, USA. Each company has detailed profile with categorisation, indication, financing rounds, products in the pipeline and many more

The user-friendly, searchable Maryland Life Sciences database will be integrated not only into the website of the Maryland Biotechnology Center but also on the USA Life Sciences Database as well as on the global Biotechgate platform. It contains profiles of relevant bioscience organizations active in Maryland across numerous sectors including biotechnology, medical devices, and investors specializing in these fields. All profiles are categorized according to sector, sub-sector and additional criteria so users can easily find the information needed.

"Global exposure is a critical factor in today's challenging environment for bioscience enterprises. Venture Valuation's capabilities have allowed us to showcase Maryland's deep R&D assets for those seeking alliances, capital, and U.S. location. It also gives our industry valuable connectivity on an unprecedented scale." said Dr. Lawrence Mahan, Acting Executive Director of the Maryland Biotechnology Center (www.marylandbiocenter.org).

"We are excited about this expansion of our partner base to the East Coast after we have been working with Biocom in San Diego, BioteCANADA and many partners in Europe. This partnership is another example of our corporate goal to provide value added global connection through our Biotechgate database" said Dr. Patrik Frei, CEO of Venture Valuation.

For further information: Dr. Patrik Frei, CEO, Venture Valuation Inc, Switzerland, +41 (43) 321 8660, p.frei (at) venturevaluation.com or Dr. Lawrence C. Mahan, Executive Director (acting), Maryland Biotechnology Center, USA, +1 (410) 767 6371, lmahan (at) choosemaryland.org

About us:

Venture Valuation (www.venturevaluation.com)

Venture Valuation specializes in independent, third party assessment, valuation and monitoring of emerging high growth companies in industries such as biotechnology, med-tech and high-tech. Services are provided in the form of independent Valuation Reports to entrepreneurs (seed to pre-IPO) and investors. With offices in Switzerland, Germany, Canada and Asia, Venture Valuation has an experienced team of scientists and business professionals with expertise in finance, biotechnology, pharmaceutical and high technology industries. Furthermore, Venture Valuation has initiated, maintains and further develops the Biotech and Life Sciences Database Biotechgate (www.biotechgate.com), along with many country databases. Austria (www.austrianbiotech.com), Canada (www.canadianlifesciences.com), France (www.frenchbiotech.com), Germany (www.germanbiotech.com), Italy (www.italianbiotech.com), India (www.indianbiotech.com), Scandinavia (www.scandinavianlifesciences.com), Switzerland (www.swisslifesciences.com), UK (www.ukbiotech.com) and the US (www.usalifesciences.com).